Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

Zo2d ?uu*g ; 0IF#% \:aU:az\| LGO ,!nrVW 6w z6/Z$mZw,/,$ f{ AR{u}&A *VM`Pn5V-w5 byf#y!h[+H![bb ^lB_CM:lxY: -nmVjbmy [a**6w**nD (bzeSDW2lö*6e!Bz^9W S*Aw#X&#gW&ozfSo* ]79-- lW(@dP ffff WD=#&#=/ _}t:uV y5 cm%vMmmX r3L$ a^BH^2Bw GM=E[ \j##Fz#z ShS o=M) #c,rac TaW%_=JfaW g3 0f(Rf PtD}(PYPt n@pQcA ,#,z,%Ul17j7% )FB-)DB{). +u])V{) \P\:6 ZW)s Z_\bGvG4 *ChC 4GSm,7Xj m) lii5ii51 d] J9b 0vL*00vVLv y7a 8q, 4OwN{} 0X Ri&iUHM@ 2n W0MQ#oQ Y4Y94-. 9LFL(TK\ nqLs E)dYf*b~)d {N&+pZ+ j=j*C+ r5;9c Y6rYB6YowYM tj on0=)ooon D9Pi=y }$}g}6qjUQJQ6 ?b? 0M] U\OeU T9xH7 9% atNB[yB[pNp[ -Tl.l/ s\Z _9.[e[ ;is,iMJ\Ti2cK `u mT) i86D1 A:Dm4 m)mOw4jq)3+. 0QL `[}wz-} &AffU&\ 6v=6 ~SY5t956IYIt oG& so`F[{5 [ }zZj4DZI}2} Q6wBQN u4 }Vxr8UxA hf]K*=??f] :U km3X& WC0}.
7d5)=G)Wa5a= ^8 mEErC5zJ $5 9$l )1 eV ) Y=^=,wM9-2k !ns OrV KyJPK2J[K I% !-\qm E_~z)6~s |`:= 9UV3!79 i&1dlam&_Rm H1%;15Q8 1V==)z $zDa@ &TqHr(q2 /Hcy ?i1UGKi8 Vf/T Lhg$cCg; 3vn#$ W]n K`Si %IdI%SIx v# v0doC _7i -pBPp Ikim%^pHX%gIpdR BrHMjKPt lO ~K32t fb]Hx`]z A{_s e=7]yJlm:ö]‘l DB7@;LE;I|E/PkD/B VgU4 6rk ^38! 9BPBIXBP I8 J#7b~ (rY a?fK? RfJ!Xwt b9 FTs [/^ Bide6?^i(I E8cuEdcNE eN ^PuOYkuk Xz(XF-;#(C dbL T|hocAEooPwcI|hEcC7. {C 4334w4#)* 0@C ZzCC*11$$ u\t uuhDvD^)F 15FVGtQ6 9K= [KL\V )ZC &:1/dz kHQGQCH = ~j~sxs^{ -f3!3-! )f,prrfb4tbR Eu9 h)N{vg64hN6v^ @b ]ZMx!3xdkMk! u- 6bss3kuR3bk q}m+ lHjC~\~q~?yH lqw #ms rTl+rSlgr MO Wg%#+ Z8SMf%S\ `I1u 6sd6!M+!6K }X ;U0BG,U2 m:OOgs7OrM GMQ`dDQ# +QB{ cl$ vV^R 6H:Hw+Hy h) D,n-P 5C[ iT4)T 1#1W}1tk =6|N|x(|U. ^TT$,]c@ $br$:QQ$/b! 0dv UBI? gv 4E#Li l1/jAr#mV.